Drug Trial Radar · NCT04249323
Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Feb 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
110
Actual
Start
Jan 27, 2020
Primary completion
Oct 15, 2020
Study completion Oct 15, 2020
Sponsor
- Lead sponsor
- Corcept TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a 3-part, first-in-human study of single ascending doses (SAD; Part 1) and multiple ascending doses (MAD; Part 2) of CORT113176 in healthy participants; Part 3 is an optional part to investigate whether CORT113176 ameliorates the effects of prednisone on various pharmacodynamic (PD) endpoints. The 3 parts may not be conducted entirely sequentially provided that this is justified by pharmacokinetic (PK) and safety data obtained from completed cohorts. The first MAD cohort will not start until data are available from at least 2 SAD levels to allow MAD administration in the fasted state, or until after a food-effect cohort has been dosed in the SAD phase to allow MAD administration in the fed state. The expected exposure for the daily MAD level at steady state (taking into consideration potential accumulation on repeat dosing) must not exceed the highest exposure considered to be safe and well tolerated during preceding SAD cohorts.
Conditions
- Healthy Adults
Interventions
CORT113176 Lipid Capsule FormulationDrug
CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
Placebo matching CORT113176 Lipid Capsule FormulationDrug
Placebo matching CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration
PrednisoneDrug
Prednisone standard release tablets 1 x 20 mg plus 1 x 5 mg for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with One or More Adverse EventsTime frame: Part 1 SAD Cohorts: up to Day 9; Part 2 MAD Cohorts: up to Day 23; Part 3 Cohort: up to Day 19
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences
Ruddington, Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.